Duopharma Biotech Bhd is set to leverage increased manufacturing capacity following the commissioning of its new K3 facility in Klang, with analysts projecting full utilisation within the next three years.
The new facility has boosted Duopharma’s overall manufacturing capacity by approximately 50%. TA Research reported that management has successfully relocated 90% of production from the legacy K1 plant, originally constructed in the 1980s, to the newly operational K3 site.
Current utilisation levels at K3 have already surpassed expectations, primarily supported by the influx of new contracts. The facility is expected to play a central role in meeting growing demand for Duopharma’s pharmaceutical products.
In addition to the K3 development, Duopharma is also advancing plans to expand its small volume injectables line at the K2 plant. The company has further outlined its intention to develop a new biological manufacturing facility at the upcoming K5 site in the coming years, signalling a strategic shift towards higher-value product segments.
This phased expansion underscores Duopharma’s long-term commitment to increasing its production capabilities and strengthening its position within the pharmaceutical industry.
-The Star
